MCP Showcase
Tirzepatide evidence brief
Name a drug asset; get a citation-auditable Word evidence brief — pivotal Phase-3 trials, grounded efficacy and safety findings, and the trial↔paper links — every figure verbatim from Amass.
New to Amass? Connect Amass to Claude first
The prompt
Paste this into Claude
tirzepatideDRUG ASSET: tirzepatide
You have the Amass MCP connected (TrialCore + BioMedCore). Assemble a one-document EVIDENCE
BRIEF for this asset — citation-auditable, every figure traceable to an Amass record.
1. PIVOTAL TRIALS. Call search_amass_trialcore_records with:
query = the DRUG ASSET, phase = "PHASE3", interventionType = "DRUG"
Keep the registrational / outcomes trials. Build a table: NCT | Acronym | Indication |
Sponsor | Status | Enrollment | Start — every field verbatim from the record.
2. EFFICACY EVIDENCE. Call search_amass_biomedcore_records with:
query = the DRUG ASSET + key indication terms, minJournalQualityJufo = 2, isRetracted = false
For each pivotal finding write one CLAIM grounded in a specific abstract. Quote the numbers
(%, kg, HR, CI, P) VERBATIM from that abstract — never rounded, never recalled. Tag each claim
with PMID, journal, JuFo tier, citationCount.
3. CROSS-CORE PROVENANCE. For one pivotal trial, call get_amass_trialcore_record and read its
referencesBiomedCore links — show the trial record pointing at its own describing paper
(NCT ↔ PMID). This is the publication↔trial graph no raw registry exposes.
4. SAFETY. Include at least one safety signal from a JuFo>=2 abstract, with its verbatim effect
size — do not soften or omit it.
5. Assemble sections 1–4 as a formatted .docx evidence brief. Close with an AUDIT TRAIL listing
every Amass ID and PMID cited, and a scope note: figures are verbatim from Amass records as of
<date>; this is an evidence digest, not regulatory advice.Why not just ask the model?
Ask a plain model for "a tirzepatide evidence brief" and it produces a fluent document with invented trial IDs, mis-remembered effect sizes, and citations that don't resolve.
- Plain model: plausible NCTs, recalled (often wrong) effect sizes, unresolvable citations.
- Amass: real TrialCore records (every NCT, sponsor, status and enrollment verbatim) plus a JuFo-gated, non-retracted corpus — the −20.8-point weight difference (PMID 37840095), the −5 mmHg systolic drop (PMID 39551891), the 2.15 retinopathy odds ratio (PMID 40637847) — each copied from the abstract, and the SUMMIT trial linked straight to its paper (NCT04847557 → PMID 39551891).
Honest scope
An evidence digest, not a label, a systematic review, or regulatory advice. The trial table is the Phase-3 drug set Amass returns for the asset, not an exhaustive program census; the efficacy and safety claims are a grounded sample of the high-quality literature, not a meta-analysis. Every figure is verbatim from an Amass record as of the run date and traceable by the PMIDs and Amass IDs in the audit trail.
More showcases
Keep exploring
| rank | title | journal | publicationDate |
|---|---|---|---|
| 1 | Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | The New England journal of medicine | 2022-02-10 |
| 2 | Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial | JAMA network open | 2023-04-03 |
| 3 | Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial | medRxiv (preprint) | 2022-09-21 |
Trial evidence trace
Paste one clinical-trial ID; get the exact published papers that describe it — pulled from Amass's publication↔trial graph, with trust metadata and abstract-grounded relevance notes.
EXPLORER-HCM - NCT03470545 (16 describing papers)
Submission Evidence Assembler - mavacamten (Camzyos)
Submission evidence assembler
Name one drug asset; get a citation-auditable, Module-2.5-style evidence narrative — every pivotal Phase-3 trial, its describing papers, and a canonical Amass-ID audit trail — assembled from Amass's publication↔trial graph with trust metadata on every cited paper.
Resmetirom evidence snapshot
Name a drug asset; get a one-page PDF evidence snapshot — regulatory status, pivotal trials, grounded efficacy figures and the trial↔paper link — every number verbatim from Amass.
Run it yourself
Connect Amass to Claude and paste the prompt.
No build, no deploy — the connector takes about a minute, then this workflow runs on your own inputs.